POPULARITY
37 episodes with car t cell therapy
19 episodes with car t cell therapy
9 episodes with car t cell therapy
9 episodes with car t cell therapy
17 episodes with car t cell therapy
8 episodes with car t cell therapy
5 episodes with car t cell therapy
7 episodes with car t cell therapy
13 episodes with car t cell therapy
5 episodes with car t cell therapy
5 episodes with car t cell therapy
5 episodes with car t cell therapy
4 episodes with car t cell therapy
6 episodes with car t cell therapy
6 episodes with car t cell therapy
7 episodes with car t cell therapy
2 episodes with car t cell therapy
5 episodes with car t cell therapy
6 episodes with car t cell therapy
5 episodes with car t cell therapy
4 episodes with car t cell therapy
5 episodes with car t cell therapy
5 episodes with car t cell therapy
4 episodes with car t cell therapy
7 episodes with car t cell therapy
3 episodes with car t cell therapy
6 episodes with car t cell therapy
5 episodes with car t cell therapy
4 episodes with car t cell therapy
3 episodes with car t cell therapy
6 episodes with car t cell therapy
4 episodes with car t cell therapy
5 episodes with car t cell therapy
2 episodes with car t cell therapy
2 episodes with car t cell therapy
2 episodes with car t cell therapy
4 episodes with car t cell therapy
6 episodes with car t cell therapy
4 episodes with car t cell therapy
4 episodes with car t cell therapy
2 episodes with car t cell therapy
3 episodes with car t cell therapy
3 episodes with car t cell therapy
3 episodes with car t cell therapy
3 episodes with car t cell therapy
In this episode of Bench to Bedside, Dr. Roy Jensen welcomes Dr. Joseph McGuirk, division director of Hematologic Malignancies and Cellular Therapies at The University of Kansas Cancer Center, to discuss CAR T-cell therapy and the growing "CAR T crisis" in access. Dr. McGuirk explains how CAR T is made from a patient's own T cells and why it has produced unprecedented, potentially curative outcomes in blood cancers such as diffuse large B-cell lymphoma, leading to FDA approvals in second- and third-line settings. He shares national data showing only 25% of eligible second-line patients and 35% of eligible third-line patients receive CAR T, with access declining as distance from a treatment center increases. The conversation highlights barriers including referral patterns, education gaps, logistics, socioeconomic factors, and disparities, and outlines KU's efforts to expand outreach, partner with community sites, and build infrastructure to improve timely evaluation and treatment. 00:00 Welcome and the CAR T Crisis 01:25 How CAR T works 05:00 Breakthrough results and approvals 06:52 The access gap data 10:16 Why delays are deadly 11:49 Barriers to referral and equity 17:31 Taking CAR T closer to home 19:37 What patients can do now 22:22 Rapid evaluation and parallel workflow 24:26 New cancer center and GMP expansion 28:46 Closing thoughts and resources Links from this Episode: Learn more about CAR T treatment at KU Cancer Center Learn more about Dr. Joseph McGuirk Read Dr. McGuirk's research "Real-world treatment patterns and survival outcomes in second and third line settings in large B-cell lymphoma (LBCL)" Read Dr. McGuirk's article "Leading Oncologist Rings the Alarm Bell: 'We Have a Crisis in Life-Saving Access to CAR T-Cell Therapy' Hear Dr. McGuirk talk about CAR T access on KCUR's "Up to Date" podcast To ensure you get our latest updates, follow us on the social media channel of your choice by searching for KU Cancer Center.
Drs. Wierda and O'Brien discuss how fixed-duration venetoclax-based therapy can match continuous BTK inhibitor treatment in CLL while offering deep remissions and time off therapy. They also explore promising real-world CAR T-cell (liso-cel) results and stress the growing importance of vaccination and cancer screening as CLL patients live longer.
MS-Perspektive - der Multiple Sklerose Podcast mit Nele Handwerker
Die EMSP 2026 Konferenz in Berlin hat mir einmal mehr gezeigt, wie viel sich aktuell in der Welt der Multiplen Sklerose (MS) bewegt – und wie wichtig es ist, dass wir als Betroffene unsere Stimme einbringen. Ich nehme dich in dieser Folge mit hinter die Kulissen der Konferenz: von bewegenden persönlichen Geschichten über neue Diagnosekriterien bis hin zu aktuellen Therapieansätzen und den großen Herausforderungen in der Versorgung innerhalb Europas.
Would like like to share feedback on this podcast? Or suggest another topic for us to explore? Click here, or email us at DocTalk@medstar.netOn this DocTalk episode, we chat with Dr. Jennifer Kanakry, the medical director of the Stem Cell Transplant and Cellular Immunotherapy Program at MedStar Georgetown University Hospital. Dr. Kanakry explains what types of lymphoma can be treated with CAR T-cell therapy. For an interview with Dr. Jennifer Kanakry, or for more information about this podcast, contact MedStar Georgetown University Hospital Manager Media Relations, Ryan.M.Miller2@Medstar.net. Learn more about Dr. Kanakry.For more episodes of MedStar Health DocTalk, go to medstarhealth.org/doctalk.
We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech we're speaking with Alan Bash, President, Carvykti, at Legend Biotech, about how Carvykti became a blockbuster, category-leading CAR T therapy for multiple myeloma. Alan talks about manufacturing and delivering an autologous cell therapy at commercial scale, Legend Biotech's partnership with Johnson & Johnson, lessons he learned at Bristol Myers Squibb, Checkmate Pharmaceuticals, and ZielBio, and his strategy for growing Carvykti's patient footprint and facing new competitors in the market. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/
"You want to try to act quickly and be able to know what the pathways are for appropriate escalating when a patient is having symptoms that are reflective of cytokine release syndrome (CRS) or neurotoxicity. These toxicities are very manageable and treatable when recognized early. To summarize, choosing the right patient, knowing the toxicity profile for each product, and acting early is really what helps to prevent severe outcomes with chimeric antigen receptor (CAR) T-cell therapy," Maribel Pereiras, PharmD, BCPS, BCOP, clinical pharmacy specialist at the John Theurer Cancer Center at Hackensack University Medical Center in New Jersey, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about CAR T-cell immunotherapy. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Earn 0.75 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by March 20, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to CAR T-Cell immunotherapy in the treatment of cancer. Episode Notes Complete this evaluation for free NCPD. ONS Podcast™ episodes: Pharmacology 101 series Episode 267: Side-Effect Management for CAR T-Cell Therapy for Hematologic Malignancies Episode 261: CAR T-Cell Therapy for Hematologic Malignancies Requires Education and Navigation Episode 176: Oncologic Emergencies 101: Cytokine Release Syndrome ONS Voice articles: A Body of Evidence Helps Nurses Manage CAR T-Cell Therapy Toxicities CAR T-Cell Therapy Programs Oncology Clinical Social Workers Add Layers of Support for Patients and Families During CAR T-Cell Therapy Studies Show Best Practices to Manage CAR T-Cell Therapies' irAEs and Improve Outcomes ONS Voice oncology drug reference sheet: Lisocabtagene Maraleucel Clinical Journal of Oncology Nursing articles: CAR T-Cell Therapy for Relapsed/Refractory Aggressive Large B-Cell Lymphoma CAR T-Cell Therapy: Updates in Nursing Management Nursing Considerations in Navigating Patients Receiving CAR T-Cell Therapy ONS book: Guide to Cancer Immunotherapy (second edition) ONS Huddle Cards: Chimeric Antigen Receptor T-Cell Therapy Cytokine Release Syndrome Immune Effector Cell–Associated Neurotoxicity Syndrome Immunotherapy Immuno-Oncology Learning Library American Society of Gene and Cell Therapy: Learning Center American Society for Transplantation and Cellular Therapy: Learning Center National Comprehensive Cancer Network home page To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "CAR T-cell therapy combines an adoptive cell transfer with genetic engineering. And what that really means is that we are harvesting a patient's own T cells and then we engineer them with a synthetic receptor that helps them recognize that cancer. And all of this work has evolved through many decades of stepwise advances in how we design and activate the T cells. That led us to several landmark trials and ultimately the first CAR T-cell therapy approved by the U.S. Food and Drug Administration in 2017, which was tisagenlecleucel for pediatric and young adult patients that had acute lymphoblastic leukemia." TS 3:34 "If a patient has higher disease burden or an inflammatory biology, that does tend to correlate with higher toxicity risk. And then that might influence the way we monitor the patients who are getting the CAR T therapy. And then finally, baseline neurologic examinations, because neurotoxicity can occur with these agents. It's very important that we as a whole healthcare team really understand what the patient looks like at baseline to be able to determine if they're having any altered changes or confusion. If I had to summarize it, we want to confirm the target and make sure that we have the right CAR T product for the patient. We want to confirm that the patient, physiologically and mentally, is ready for the CAR T therapy." TS 10:53 "I think the two [toxicities] that every nurse will hear about almost immediately when talking about CAR T therapy are CRS or ICANS, which stands for immune effector cell–associated neurotoxicity syndrome. ... ICANS can either follow or even occur alongside CRS. And this can present as something as simple as just being slightly confused or altered, leading into progressively more severe elements such as word-finding difficulties, tremors, or changes in handwriting. Or even more severe cases that lead to seizures or decreased levels of consciousness. So, in this setting, neurologic assessments and knowing and understanding what your patient's baseline neurologic status is is so important. Those are really the two largest side effects that cross the board when it comes to CAR T therapies." TS 16:02 "In terms of the more practical aspects of administration, this is not a typical medication infusion. CAR T cells are living cells. So the way they are handled and administered is very specific. The majority of CAR T products are given as a single IV infusion. The cells come to us frozen either from a cellular lab or they will come from the pharmacy department. So those cells are typically thawed, and timing is of the essence. You really need to coordinate the timing of [thawing] to when they get infused to your patient. They tend to have a short shelf life once they're not frozen anymore." TS 26:34 "Now that therapy has, in many places, transitioned to be administered in the outpatient setting, education becomes absolutely critical. The patient is coming for their daily visit to clinic and then they're going home. And it's really up to the caregiver, who is usually not a nurse, who has to recognize early signs of toxicity. They need to be educated about what a fever is, what number constitutes a fever, what does confusion look like, what does hypotension look like? ... Do they have access to a thermometer? If you are asking them to look at blood pressure, do they have access to a blood pressure monitor? And sometimes those can be subtle things that might be overlooked. So, the emphasis in outpatient quality education is teaching those caregivers what to watch for, how to act quickly, and who to call immediately. You need to make sure that they have that information readily available if something happens." TS 30:55
Analysis from Pew shows state reserve funds — often called rainy day funds — largely fell in 2025. That's the first time that happened since the Great Recession. It's down from a record high for state rainy day funds nationwide just the prior year. But Louisiana actually had a record-high rainy day balance in 2025, but we can't rest easy, as it still falls short of the national average. To learn more about what this means and how the state uses reserve funds, we're joined by Page Forrest, associate manager of the Fiscal 50 project at The Pew Charitable Trusts. This Friday, LSU's Reilly Center for Media and Public Affairs will present its 2026 John Breaux Symposium. The topic: “American Media at 250.”They will be exploring the influence the media has exerted over civic life in America over the past two and a half centuries, as the U.S. approaches its 250th birthday.Michael DiResto, director of the Reilly Center at LSU, tells us more about the upcoming event that highlights centuries of American political journalism. Earlier this year, Mary Bird Perkins Cancer Center in Baton Rouge became the first hospital in the region to offer a certain type of cancer immunotherapy — referred to as CAR-T-Cell Therapy — on an outpatient basis for certain blood cancers.Dr. Andrew Dalovisio, director of the Myeloma Lymphoma and Cellular Therapy Program at Mary Bird Perkins, tells us more about this life-saving treatment.—Today's episode of Louisiana Considered was hosted by Adam Vos. Our managing producer is Alana Schreiber. We get production support from Garrett Pittman and our assistant producer, Aubry Procell.You can listen to Louisiana Considered Monday through Friday at noon and 7 p.m. It's available on Spotify, the NPR App and wherever you get your podcasts. Louisiana Considered wants to hear from you!Please fill out our pitch line to let us know what kinds of story ideas you have for our show. And while you're at it, fill out our listener survey! We want to keep bringing you the kinds of conversations you'd like to listen to.Louisiana Considered is made possible with support from our listeners. Thank you!
T cell and immune cell engagement is gaining traction, but what makes it different from other therapies? Patrick Baeuerle, Ph.D., chief scientific advisor at Cullinan Therapeutics, and Jeffrey Miller, M.D., deputy director of Masonic Cancer Center, join The Chain to discuss the advantages, similarities, and differences of T cell and immune cell engagers, and how they compare to other modalities such as CAR T cells. Hosted by Laszlo Radvanyi, Ph.D., their conversation covers engineering recognition of multiple targets, prospects for peptide MHC engagers and NK cells engagers, and the application of these modalities to oncology and beyond. Links from this episode: University of Toronto, Department of Immunology University of Toronto Cullinan Therapeutics Masonic Cancer Center
Cancer treatment has long been a battle of attrition—surgery, radiation, and chemotherapy have saved countless lives, but for patients with advanced or refractory malignancies, the options remain limited. In recent years, however, a new approach has emerged that harnesses the power of the patient's own immune system to seek and destroy cancer cells with unprecedented precision. An editorial perspective, titled “CAR-T therapy: Trailblazing CAR(ing) in cancer treatment.” published in Volume 17 of Oncotarget by researchers Uzma Saqib, Monika Pandey, and Krishnan Hajela from the School of Life Sciences, Devi Ahilya Vishwavidyalaya, Indore, India, provides an overview of this revolutionary therapeutic strategy. The paper presents the current state of CAR-T therapy, its clinical successes, and the formidable challenges that remain before it can fulfill its transformative potential. Full blog - https://www.oncotarget.org/2026/03/10/car-t-cell-therapy-a-revolutionary-approach-to-cancer-treatment/ Paper DOI - https://doi.org/10.18632/oncotarget.28836 Correspondence to - Krishnan Hajela - hajelak@gmail.com Abstract video - https://www.youtube.com/watch?v=T4hbwPToVKI Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28836 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, CAR-T therapy, therapeutic approaches To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM
Dr. Alex Marson, MD, PhD, is a professor of medicine at the University of California, San Francisco. We discuss the biology of the immune system and cancer, and everyday choices that can increase or decrease your cancer risk, several of which are surprising but all of which are actionable. We also discuss immunotherapy, including how engineered T-cells can be used to defeat childhood and adult cancers. Dr. Marson explains CRISPR and gene editing to cure diseases, and we address the ethical questions surrounding gene editing in embryos, children and adults. This discussion is for anyone interested in avoiding cancer and/or seeking to understand the science and practical applications of immune- or gene-therapy. Read the show notes at hubermanlab.com. Thank you to our sponsors AG1: https://drinkag1.com/huberman BetterHelp: https://betterhelp.com/huberman Helix Sleep: https://helixsleep.com/huberman LMNT: https://drinklmnt.com/huberman Function: https://functionhealth.com/huberman Timestamps (00:00:00) Alex Marson (00:02:21) Diseases & Current Biological Landscape; AI & Computational Tools (00:05:56) Immune System, Innate vs Adaptive Immune System (00:10:55) Thymus, T Cell Selection; B Cells & Antibodies (00:13:23) Sponsors: BetterHelp & Helix Sleep (00:16:11) Immune System Health, Sleep, Diet; Genes (00:20:56) Childhood Exposure & Allergy Prevention; Autoimmune Reactions (00:25:27) Whole Body Immune Response, Cytokines & Fever; Antibiotics (00:30:51) Cancer; Mutations & Cell Regulation; Smoking, BRCA Mutations, Sunlight (00:38:27) BRAC Mutations, Mutagens, Pesticides (00:42:33) Sponsor: AG1 (00:43:57) X-Rays & Airport Scanners, Carcinogen vs Mutagen, Charred Meat, Food Dye (00:49:34) Immune-Based Cancer Treatment, Checkpoint Inhibitors, CAR T-Cell Therapy (00:59:04) CRISPR, Immunotherapies (01:02:52) Age & Cancer Risk; CAR T-Cells, Targets & Side Effects; Ketogenic Diet (01:08:27) CRISPR Discovery & Mechanism (01:17:06) CRISPR Precision, Risk & Benefit; CRISPR Technology Evolution (01:20:57) Sponsor: LMNT (01:22:17) CRISPR Cell Delivery, Clinical Trials; Treating Early Cancers & Prevention (01:33:47) Liposomes, Engineered Viruses, Lipid Nanoparticles (LNPs), Vaccines (01:39:57) COVID Pandemic & Trust in Science, mRNA Vaccine (01:47:51) Sponsor: Function (01:49:39) Drug Delivery to Cancer, Immunotoxins, T-Cell Engagers; AI Protein Targets (01:55:45) CRISPR Embryo Modification, Ethics; Heritable Gene Editing, Diversity (02:05:42) Deep Sequencing Embryos, Diversity; Overcoming Adversity & Resilience (02:10:44) Upcoming Therapeutics, Autoimmunity & CAR T-Cells, CRISPR & Gene Function (02:17:55) Banking T Cells or iPSCs?, Future of Cell Programming (02:24:41) Zero-Cost Support, YouTube, Spotify & Apple Follow, Reviews & Feedback, Sponsors, Protocols Book, Social Media, Neural Network Newsletter Disclaimer & Disclosures Learn more about your ad choices. Visit megaphone.fm/adchoices
CAR T‑cell therapy is redefining what personalized cancer treatment can look like, offering real promise for patients and families. In this episode, we speak with Dr. Richard Maziarz and CAR T Nurse Coordinator Bashi Ratterree of Oregon Health & Science University (OHSU). Together, they explain how CAR T‑cell therapy works, who may be eligible, what patients can expect during treatment and recovery, and the promising advancements shaping the future of this innovative therapy. DOWNLOAD TRANSCRIPT CLICK HERE to participate in our episode survey. Mentioned on this episode: CAR T-cell therapy Clinical Trial Support Center CAR T-Cell Therapy: A Path of Hope and Healing Video Series Bloodline Breakthroughs: innovations and inspiration video podcast: CAR T-cell Therapy Hematology Horizons vlog: CAR T-Cell Therapy and the Patient Experience CAR T-Cell Therapy: Side Effects video Additional Blood Cancer United Support Resources: Information Specialists Financial support Online Chat Free Nutrition Consultations Free telephone/web patient programs Free booklets Young Adult Resources Support groups Caregiver support Caregiver Workbook Survivorship Workbook Advocacy and Public Policy Patient Community Mental Health Resources Episode supported by Bristol Myers Squibb; Johnson & Johnson & Legend Biotech; Kite, a Gilead Company; Novartis Pharmaceuticals Corporation. The post Inside CAR T‑Cell Therapy: How Innovation Is Changing Lives first appeared on The Bloodline with Blood Cancer United Podcast.
There's growing calls to find pathways to bring CAR-T cell therapy to New Zealand. The current trial of the life changing cancer treatment is set to end at later this year, but there's no clear path to making it available through the public health system. Malaghan Institute Clinical Director Rob Weinkove says this treatment will improve many people's outcomes. "Much of the infrastructure is there and I think one of the main motivations of setting up this trial here is just to skill up, because it's clear the big international pharmacies weren't going to come to New Zealand, we're a small market." LISTEN ABOVESee omnystudio.com/listener for privacy information.
Host: Brian P. McDonough, MD, FAAFP Guest: Tara Graff, DO, MS Guest: Surbhi Sidana, MD While BCMA-directed CAR T-cell therapy has changed the treatment landscape for patients with relapsed and refractory (R/R) multiple myeloma, access remains uneven outside academic centers. In this expert-led discussion, Dr. Brian McDonough, Dr. Surbhi Sidana, and Dr. Tara Graff explore real-world barriers to referral and delivery, evolving care models, and the multidisciplinary coordination required to extend CAR T therapy into community practice. Dr. Sidana is an Associate Professor of Medicine, and she leads the Myeloma CAR T and Immunotherapy program at Stanford Medicine. Dr. Graff is the Director of Clinical Research at Mission Cancer + Blood, and she serves on the National CAR T-Cell Advisory Board for Multiple Myeloma.
The first coordinated global research strategy to prevent MS has been announced. This week, Dr. Bruce Bebo, the National MS Society's Executive Vice President and Chief Research & Medical Affairs Officer, joins me to explain what MS prevention looks like and how experts plan to achieve this remarkable goal. We'll also tell you who won the 2025 Barancik Prize for Innovation in MS Research, and we'll explain how their groundbreaking research impacts MS care. We're sharing the details of a newly announced partnership designed to reduce delays in getting an MS diagnosis and expand access to MS care in Wisconsin. We'll tell you how an international drug discovery network found that a drug already approved for another condition could also protect nerve cells and promote remyelination. And we'll share research that shows that AI can accurately predict whether someone newly diagnosed with MS will experience progression independent of relapse activity (PIRA) in the three years following their diagnosis. We have a lot to talk about! Are you ready for RealTalk MS??! I'm asking for your support: :22 This Week: Preventing MS 1:47 Dr. Manuel Friese is the winner of the 2025 Barancik Prize for Innovation in MS Research 2:41 National MS Society announces a partnership to improve time to MS diagnosis and access to MS care in Wisconsin 6:26 An international drug discovery network identifies a drug that protects nerve cells and promotes remyelination 8:05 STUDY: AI accurately predicts progression independent of relapse activity in individuals who are newly diagnosed with MS 10:51 Dr. Bruce Bebo explains the strategy behind the global research initiative to prevent MS 14:48 Share this episode 31:31 SHARE THIS EPISODE OF REALTALK MS Just copy this link & paste it into your text or email: https://realtalkms.com/439 ADD YOUR VOICE TO THE CONVERSATION I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts! Email: jon@realtalkms.com Phone: (310) 526-2283 And don't forget to join us in the RealTalk MS Facebook group! LINKS If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com Support Jon at WALK MS https://realtalkms.com/walkms RealTalk MS Episode 424: I'm a Participant in a Clinical Trial for CAR T-Cell Therapy for MS with Jan Janisch-Hanzlik https://realtalkms.com/424 STUDY: In Silico Screening and Preclinical Validation Identify Bavisant as a Therapeutic Candidate for Multiple Sclerosis https://science.org/doi/10.1126/scitranslmed.ads0633 STUDY: Machine Learning Analysis Applied to Prediction of Early Progression Independent of Relapse Activity in Multiple Sclerosis Patients https://onlinelibrary.wiley.com/doi/10.1111/ene.70417 Find out about ABLEnow Accounts https://ablenow.com JOIN: The RealTalk MS Facebook Group https://facebook.com/groups/realtalkms REVIEW: Give RealTalk MS a rating and review http://www.realtalkms.com/review Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com. RealTalk MS Episode 439 Guests: Dr. Bruce Bebo Privacy Policy
Guests:Dr Larry Bacon, Consultant Haematologist from St James's HospitalDr Nicola Gardiner, Chief Medical Scientist at the Cryobiology Laboratory Stem Cell Facility at St James's
Featuring perspectives from Dr Jeremy S Abramson and Dr Loretta J Nastoupil, including the following topics: Overview of Chimeric Antigen Receptor (CAR) T-Cell Therapy (0:00) Potential Treatment Benefits of CAR T-Cell Therapy (13:31) Cytokine Release Syndrome and Immune Effector Cell-Associated Neurotoxicity Syndrome (28:13) Finding Information About CAR T-Cell Therapy; Clinical Trials (36:28) Financial Issues; Risk of Infection (42:02) Coping with Anxiety; Healing and Moving On (53:27) CME information and select publications
Dr Jeremy S Abramson from Massachusetts General Hospital in Boston and Dr Loretta J Nastoupil from CommonSpirit Mercy Hospital in Durango, Colorado, discuss the clinical applications of chimeric antigen receptor T-cell therapy for patients with non-Hodgkin lymphoma. CME information and select publications here.
CAR T-cell therapy is a potentially life-saving treatment for patients with certain hematologic malignancies. Yet, the logistical challenges and the need for specialized management of adverse events have limited its availability in community settings. In this episode, CANCER BUZZ speaks with Jeremy M. Pantin, MD, FACP, clinical director of the Adult Transplant and Cellular Therapy Program at TriStar Centennial Medical Center, part of the Sarah Cannon Transplant and Cellular Therapy Network. Dr. Pantin discusses the cancer center's community-based, outpatient model, impact on outcomes for patients with hematologic malignancies, and shares his perspective on future changes needed to help further expand access to CAR T-cell therapy. "Education of community oncology staff at their offices—coordinators, nurses, physicians, advanced practice providers—also goes a long way in helping facilitate patients to be recognized when they are candidates for cell therapy." - Jeremy M. Pantin, MD, FACP "It did not matter the distance to the center; did not matter the socioeconomic background. Many of the other factors one would think would lead to decreased access, we did not find among our centers. It was really the delay from consult to treatment." - Jeremy M. Pantin, MD, FACP Guest: Jeremy M. Pantin, MD, FACP Clinical Director, Adult Transplant and Cellular Therapy Program Sarah Cannon Transplant and Cellular Therapy Network At TriStar Centennial Medical Center Nashville, TN Resources: Bringing CAR T-Cell Therapies to Community Oncology Outpatient Administration of Chimeric Antigen Receptor T-Cell Therapy Using Remote Patient Monitoring FDA Eliminates Risk Evaluation and Mitigation Strategies (REMS) for Autologous Chimeric Antigen Receptor CAR T cell Immunotherapies
Welcome to a RealTalk MS special series on MS clinical trials. This special series is made possible through a generous grant from Sanofi. In this final episode of this series, you'll meet Jan Janisch-Hanzlik. Jan lives with MS and is a participant in one of the clinical trials evaluating the safety and efficacy of CAR-T cell therapy for MS. In CAR-T cell therapy, blood is taken from the patient or a healthy donor, much as you would donate blood. This blood is sent to a lab, where the white blood cells, or T-cells, are separated out and reprogrammed to carry a receptor designed to fight a particular condition. This receptor is known as a chimeric antigen receptor, or CAR. Over several weeks in the lab, these fortified T-cells multiply until there are millions of them, then they're reintroduced to the patient by intravenous infusion. CAR-T cell therapy is already used to treat some blood cancers, and Jan is the first person in the world to receive this one-and-done treatment to treat MS. She's joining us to share her experience participating in the clinical trial and to give us an update on how she's doing following her treatment. This special episode of RealTalk MS is made possible by a generous grant from Sanofi. Sanofi has two ongoing Phase 3 clinical trials in MS studying Frexalimab, an investigational second-generation anti-CD40 ligand monoclonal antibody. If you are interested in learning more about these clinical trials, please visit SanofiStudies.com SHARE THIS EPISODE OF REALTALK MS Just copy this link & paste it into your text or email: https://realtalkms.com/ct4 ADD YOUR VOICE TO THE CONVERSATION I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts! Email: jon@realtalkms.com Phone: (310) 526-2283 And don't forget to join us in the RealTalk MS Facebook group! Privacy Policy
Drs. Danilov and Coombs review the evolving treatment strategies for CLL, focusing on the use of CAR T-cell therapy and allogeneic stem cell transplant in different disease stages, particularly for patients with relapsed or refractory disease. They emphasize the importance of tailoring treatment to individual patient needs, considering clinical trials, and recognizing challenges.
Featuring an interview with Dr Matthew Lunning, including the following topics: Reflection on the advances made in chimeric antigen receptor (CAR) T-cell therapy (0:00) Overview of the CAR T-cell therapy administration process (4:40) Opportunities for referral for CAR T-cell therapy (10:05) Selection of a CAR T-cell therapy based on patient characteristics (16:09) Sequencing of CAR T-cell therapy for various non-Hodgkin lymphomas (23:23) Safety regulations and mitigation strategies for adverse events (30:36) Case: A woman in her early 80s with relapsed/refractory (R/R) diffuse large B-cell lymphoma receives lisocabtagene maraleucel (36:16) Case: A man in his early 60s with R/R mantle cell lymphoma receives brexucabtagene autoleucel (43:09) Case: A man in his early 60s with R/R multiple myeloma receives ciltacabtagene autoleucel (49:09) CME information and select publications
Featuring a slide presentation and related discussion from Dr Matthew Lunning, including the following topics: Overview of available chimeric antigen receptor (CAR) T-cell therapies (0:00) Toxicities associated with CAR T-cell therapy (4:03) Mitigation strategies for adverse events (22:02) Novel strategies for outpatient infusion (26:34) Changes to the CAR T-cell therapy safety regulations (30:23) CME information and select publications
Dr Matthew Lunning from the Fred and Pamela Buffett Cancer Center in Omaha, Nebraska, discusses recent updates on the management of toxicities associated with CAR T-cell therapy. CME information and select publications here.
Send us a textWe are so excited to have Dr. Yasmin Mohseni back to to talk about the latest advances in the world of immunology! We discuss the recent Nobel Prize awarded for research on regulatory T cells (Tregs) and how they help keep inflammation and autoimmunity in check. We talk about the complexities of autoimmune diseases, particularly Inflammatory Bowel Disease (IBD), and why Tregs play such a big role in keeping the immune system balanced. Dr. Mohseni walks us through some of the most innovative treatments on the horizon, from cell therapies to CAR T-cell approaches, and even how AI might shape the future of medicine. We wrap things up on a hopeful note, looking ahead at where autoimmune treatments are going and why ongoing research matters more than ever.Dr. Yasmin Mohseni, PhD is an immunologist with 6+ years of experience in the cell and gene therapy biotech space, specializing in immunotherapy for cancer and immunoregulation. Dr Mohseni earned her PhD in Immunotherapy from King's College London, where she focused on using engineered regulatory T cells (Tregs) to promote immune tolerance in solid organ transplantation with applications to autoimmunity. She began her industry journey at Quell Therapeutics, advancing Treg-based therapies, and now works at A2 Biotherapeutics in the cancer immunotherapy space, developing therapies for solid tumors. Find Dr Yas here: https://www.instagram.com/doctor.yas_/Takeaways-- Tregs are crucial for suppressing inflammation in the immune system.- The Nobel Prize recognition highlights the importance of Tregs in immunology.- Autoimmunity involves a complex interplay of genetic and environmental factors.- Tregs can be dysfunctional in autoimmune diseases, leading to chronic inflammation.- Cell therapy, including CAR T-cells, shows promise for treating autoimmune diseases.- AI is revolutionizing target discovery in immunology and personalized medicine.- The future of autoimmune treatments is hopeful, with ongoing research and innovation.- Understanding the mechanisms of Tregs can lead to better therapeutic strategies.- The balance of immune responses is critical in managing autoimmune diseases.Chapters-00:00- Introduction and Personal Updates03:40- Nobel Prize in Immunology: Tregs and Their Significance10:34- Understanding Autoimmunity and Inflammatory Bowel Disease (IBD)16:12- The Role of Tregs in Autoimmunity21:49- Exploring Cell Therapy and CAR T-Cell Approaches27:26- Future of Autoimmunity Treatments and AI in Medicine46:36- Conclusion and Future PerspectivesFollow us on instagram @crohns_and_colitis_dietitiansFollow us on youtube @thecrohnscolitisdietitiansWe love helping provide quality content on IBD nutrition and making it more accessible to all through our podcast, instagram and youtube channel. Creating the resources we provide comes at a significant cost to us. We dream of a day where we can provide even more free education, guidance and support to those with IBD like us. We need your support to do this. You can help us by liking episodes, sharing them on your social media, subscribing to you tube and telling others about us (your doctors, friends, family, forums/reddit etc). Can you do this for us? In return, I promise to continually level up what we do here.
Drs. Danilov and Coombs explore the potential benefits and challenges of CAR T-cell therapy in CLL, emphasizing the importance of personalized treatment decisions and shared decision-making between physicians and patients.
In a conversation with CancerNetwork®, Michael Barish, PhD, spoke about an investigational CAR T-cell therapy that he and colleagues are developing as a treatment for patients with glioblastoma. He and his team designed the agent to harness chlorotoxin, an amino acid peptide toxin component of scorpion venom, as a vehicle for intratumoral delivery of therapy for this patient population. Barish, a chair in the Department of Neurosciences/Developmental & Stem Cell Biology at City of Hope, discussed the background and mechanisms surrounding this novel compound, which he and colleagues evaluated as part of a phase 1 trial (NCT04214392). Early findings published in Cell Reports Medicine showed that among 4 patients with recurrent glioblastoma, 3 (75%) achieved a best response of stable disease. Additionally, the chlorotoxin-directed cellular therapy was found to be well-tolerated with no dose-limiting toxicities. Although responses were not as strong as Barish and colleagues had hoped, he described how the study nevertheless demonstrated the safety and feasibility of this CAR T-cell therapy formulation. After establishing the safety of the novel agent in patients with recurrent glioblastoma, Barish highlighted how next steps for research included engineering different versions of the chlorotoxin and modifying the T cells that express the chimeric receptor. He stated these reconfigurations may help yield additional power and efficacy of the cellular therapy in future studies. Overall, Barish noted how the potential therapeutic application of the neurotoxin represented a “proof of principle.” “[V]enoms of many invertebrates are, in fact, very powerful biologically. In a sense, evolution has honed them to be relatively specific. Neurobiology is very much driven by the specificity of different toxins for different ion channels,” Barish stated. “This idea—that one could use biological products efficiently this way for something as heterogeneous as glioblastoma—might be an example of how it could be more efficacious for other solid tumors as well.” Reference Barish ME, Aftabizadeh M, Hibbard J, et al. Chlorotoxin-directed CAR T cell therapy for recurrent glioblastoma: interim clinical experience demonstrating feasibility and safety. Cell Rep Med. 2025;6(8):102302. doi:10.1016/j.xcrm.2025.102302.
Featuring perspectives from Dr Jeremy S Abramson and Dr Manali Kamdar, including the following topics: Introduction: About This Program (0:00) Overview of Chimeric Antigen Receptor (CAR) T-Cell Therapy (3:10) Potential Treatment Benefits of CAR T-Cell Therapy (10:35) CRS (Cytokine Release Syndrome) and ICANS (Immune Effector Cell-Associated Neurotoxicity Syndrome) (34:32) Finding Information About CAR T; Clinical Trials (42:17) Financial Issues; Risk of Infection (48:11) Coping with Anxiety; Healing and Moving On (55:17) Educational and presenter information
Dr Jeremy S Abramson from Massachusetts General Hospital in Boston and Dr Manali Kamdar from the University of Colorado Cancer Center in Aurora discuss patient questions and experiences with CAR T-cell therapy for non-Hodgkin lymphoma. Educational information and select publications here.
Dr. Alison Christy and Dr. Jennifer L. McGuire discuss neuroimaging findings linked to ICANS, exploring whether specific imaging patterns correlate with distinct neurologic symptoms. Show citation: McGuire JL, Pinto S, Erdogan EN, et al. Neuroimaging Findings in Children and Young Adults With Neurotoxicity After CAR T-Cell Therapy for B-Cell Malignancies. Neurology. 2025;105(7):e214086. doi:10.1212/WNL.0000000000214086
Dr. Alison Christy and Dr. Jennifer L. McGuire discuss neuroimaging findings linked to ICANS, exploring whether specific imaging patterns correlate with distinct neurologic symptoms. Show citation: McGuire JL, Pinto S, Erdogan EN, et al. Neuroimaging Findings in Children and Young Adults With Neurotoxicity After CAR T-Cell Therapy for B-Cell Malignancies. Neurology. 2025;105(7):e214086. doi:10.1212/WNL.0000000000214086
Dr. Alison Christy talks with Dr. Jennifer L. McGuire about neuroimaging findings linked to ICANS, exploring whether specific imaging patterns correlate with distinct neurologic symptoms. Read the related article in Neurology®. Disclosures can be found at Neurology.org.
In this episode of ASTCT's Titans of Transplant series, Dr. Taha Al-Juhaishi welcomes Dr. Sattva Neelapu of MD Anderson Cancer Center for a deep and insightful conversation on the evolution, challenges and future of CAR T therapy.From the groundbreaking ZUMA-1 trial to today's expandinglandscape of commercial CAR T products, Dr. Neelapu shares pivotal clinical experiences, lessons learned in toxicity management and reflections on mentorship and innovation. This episode offers a look at the progress made, the barriers that remain and the opportunities ahead for the next generation of leaders in cellular therapy.
In this episode, I'm joined by Dr. Burhan Chaudhry, MS neurologist and clinical lead at Bristol Myers Squibb, to discuss CAR-T cell therapy which is an innovative treatment currently enrolling in clinical trials for multiple sclerosis (MS). We dive into how CAR-T cell therapy targets B cells within the central nervous system, offering hope for both relapsing and progressive MS. Dr. Chaudhry explains what sets CAR-T apart from traditional disease modifying therapies, how to get involved in MS clinical trials, and what participants can expect throughout the process. Whether you're newly diagnosed or living with MS for years, join us for empowering strategies, expert advice, and the latest updates on breakthroughs in MS treatment! Bio on Burhan Chaudry: Dr. Burhan Chaudhry is a MS neurologist and clinical lead at Bristol Myers Squibb. His sister was diagnosed with MS when he was in medical school. This inspired him to pursue Neurology. A few years after Burhan was diagnosed with MS as well. After becoming a MS neurologist, Burhan has treated MS patients both in the US and internationally. He is currently clinical lead for a global clinical trial evaluating a novel cell therapy across the MS spectrum. Resources mentioned in this episode: Website to view CAR-T info: https://www.cartautoimmune.com/ ECTRIMS 2025 Results/Report: https://distribute.congrex.com/from.storage?image=rqetJOF1YXChDh_STAPoNpjPhysyG76sohBKnHJhR-TsF3Mvxzx13zdmic5t9umH0 Additional Resources: https://www.doctorgretchenhawley.com/insider Reach out to Me: hello@doctorgretchenhawley.com Website: www.MSingLink.com Social: ★ Facebook: https://www.facebook.com/groups/mswellness ★ Instagram: https://www.instagram.com/doctor.gretchen ★ YouTube: https://www.youtube.com/c/doctorgretchenhawley?sub_confirmation=1 → Game Changers Course: https://www.doctorgretchenhawley.com/GameChangersCourse → Total Core Program: https://www.doctorgretchenhawley.com/TotalCoreProgram → The MSing Link: https://www.doctorgretchenhawley.com/TheMSingLink
Drs Joseph Mikhael and Peter Voorhees discuss considerations for treating smoldering multiple myeloma, including recent studies and shared decision-making. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1002716. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Observation or Treatment for Smoldering Multiple Myeloma? A Systematic Review and Meta-Analysis of Randomized Controlled Studies https://pubmed.ncbi.nlm.nih.gov/40419473/ Monoclonal Gammopathy of Undetermined Significance https://www.ncbi.nlm.nih.gov/books/NBK507880/ From Criteria to Clinic: How Updated Slim CRAB Criteria Influence Multiple Myeloma Diagnostic Activity https://ascopubs.org/doi/pdf/10.1200/JCO.2024.42.16_suppl.7556 International Myeloma Working Group Risk Stratification Model for Smoldering Multiple Myeloma (SMM) https://pubmed.ncbi.nlm.nih.gov/33067414/ Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma https://pubmed.ncbi.nlm.nih.gov/39652675/ Lenalidomide-Dexamethasone Versus Observation in High-Risk Smoldering Myeloma After 12 Years of Median Follow-Up Time: A Randomized, Open-Label Study https://pubmed.ncbi.nlm.nih.gov/36067617/ Long-Term Outcome With Lenalidomide and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma https://pubmed.ncbi.nlm.nih.gov/23648667/ CD38-Directed Therapies for Management of Multiple Myeloma https://pubmed.ncbi.nlm.nih.gov/34235096/ Fixed Duration Therapy With Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone for High Risk Smoldering Multiple Myeloma – Results of the Ascent Trial https://ashpublications.org/blood/article/140/Supplement%201/1830/492739/Fixed-Duration-Therapy-with-Daratumumab Curative Strategy for High-Risk Smoldering Myeloma: Carfilzomib, Lenalidomide, and Dexamethasone (Krd) Followed by Transplant, Krd Consolidation, and Rd Maintenance https://pubmed.ncbi.nlm.nih.gov/39038268/ Early Safety and Efficacy of CAR-T Cell Therapy in Precursor Myeloma: Results of the CAR-PRISM Study Using Ciltacabtagene Autoleucel in High-Risk Smoldering Myeloma https://ashpublications.org/blood/article/144/Supplement%201/1027/531466/Early-Safety-and-Efficacy-of-CAR-T-Cell-Therapy-in
In this episode of ASTCT Talks, we're excited to share a special feature from the Pharmacy Focus: Oncology Edition podcast in honor of American Pharmacists Month, featuring members of ASTCT Pharmacy SIG. Expert pharmacists share key insights on BCMA bispecifics, CAR T-cell therapies, and other cellular treatments for multiple myeloma. Moderated by Ryan Shaw, PharmD, of the University of North Carolina at Chapel Hill, the discussion features Sara Ann Scott, PharmD, of Emory Winship Cancer Institute, and Kelley Julian, PharmD, of the University of Utah Huntsman Cancer Institute. Together, they explore treatment sequencing strategies for cellular therapies, with a focus on ciltacabtagene autoleucel and idecabtagene vicleucel.
Jan Janisch-Hanzlik lives with MS and is a participant in one of the clinical trials evaluating the safety and efficacy of CAR-T cell therapy for MS. Jan is the first person in the world to receive this one-and-done treatment, and this week, she's joining me to share her experience participating in the clinical trial. But you'll be especially interested in hearing how CAR-T cell therapy has impacted Jan's MS. Open enrollment for people with Medicare and for those who get their health insurance through the ACA healthcare.gov Marketplace begins this week, and we're talking about some of the reasons you want to pay particular attention to your 2026 health insurance options. As the U.S. federal government shutdown enters its third week, we're reviewing some of the ways that the shutdown may affect someone living with MS. And we're giving you a reminder about how you can add your voice and share your story of living with MS with the FDA by participating in the Shaping Tomorrow Together initiative. We have a lot to talk about! Are you ready for RealTalk MS??! This Week: A first-hand account of an important clinical trial, open enrollment begins, and how the government shutdown may affect people with MS :22 Open enrollment for Medicare and Marketplace enrolees begins :22 How the federal government shutdown could affect people living with MS 4:29 Your opportunity to tell the FDA what it's like to live with MS 8:57 Jan Janisch-Hanzlik shares her experience participating in a CAR-T cell therapy clinical trial, and how the treatment has impacted her MS 11:28 Share this episode 31:38 Next week's episode 31:57 SHARE THIS EPISODE OF REALTALK MS Just copy this link & paste it into your text or email: https://realtalkms.com/424 ADD YOUR VOICE TO THE CONVERSATION I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts! Email: jon@realtalkms.com Phone: (310) 526-2283 And don't forget to join us in the RealTalk MS Facebook group! LINKS If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com PARTICIPATE: Take the Shaping Tomorrow Together Survey https://s.alchemer.com/s3/Perspectives-on-MS REGISTER: Attend the virtual Shaping Tomorrow Together meeting with the FDA https://nmss.quorum.us/event/25463 SIGN UP: Become an MS Activist https://nationalmssociety.org/advocacy JOIN: The RealTalk MS Facebook Group https://facebook.com/groups/realtalkms DOWNLOAD: The RealTalk MS App for iOS Devices https://itunes.apple.com/us/app/realtalk-ms/id1436917200 DOWNLOAD: The RealTalk MS App for Android Deviceshttps://play.google.com/store/apps/details?id=tv.wizzard.android.realtalk REVIEW: Give RealTalk MS a rating and review http://www.realtalkms.com/review Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com. RealTalk MS Episode 424 Guest: Jan Janisch-Hanzlik Privacy Policy
AI Therapy: Can An Algorithm Help You More Than A Human? Will AI therapy promote even more isolation within society? Dr. Michael Heinz, a research psychiatrist, is part of a team using generative AI to act as a therapist for people with anxiety, depression, and eating disorders. Dr. Michael Heinz explains how this always-available AI therapist measures up to human-based therapy, and how AI best fits into the future of mental health.' Segment 2: CAR-T Cell Therapy: Pioneering The Future Of Cancer Treatment CAR T-cell therapy is a groundbreaking cancer treatment that reprograms a patient's own immune cells to recognize and destroy cancer. First approved by the FDA in 2017, it's already shown success in patients with blood cancers that no longer respond to standard treatments. While the therapy can cause serious side effects, our expert this week –a pioneer of this therapy– discusses the future of using this powerful new weapon against cancer. Learn more about your ad choices. Visit megaphone.fm/adchoices
CAR T-cell therapy is a groundbreaking cancer treatment that reprograms a patient's own immune cells to recognize and destroy cancer. First approved by the FDA in 2017, it's already shown success in patients with blood cancers that no longer respond to standard treatments. While the therapy can cause serious side effects, our expert this week –a pioneer of this therapy– discusses the future of using this powerful new weapon against cancer. Learn more about your ad choices. Visit megaphone.fm/adchoices
“I think that this is an area that is exploding. Working with drug development, I see new agents all the time, with unique targets I've never heard about, with targets I have heard about used in a different way. So, I really think we're going to see more and more bispecifics. A lot of these drugs are used second line, third line, fourth line. I would not be surprised if they moved up in treatment, especially as we learn safer ways to give these drugs,” ONS member Moe Schwartz, PharmD, BCOP, FHOP, professor of pharmacy practice at the James L. Winkle College of Pharmacy at the University of Cincinnati, OH, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about bispecific antibodies. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by October 3, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learner will report an increase in knowledge related to the use of bispecific antibodies in the treatment of cancer. Episode Notes Complete this evaluation for free NCPD. ONS Podcast™ episodes: Pharmacology 101 series Episode 275: Bispecific Monoclonal Antibodies in Hematologic Cancers and Solid Tumors Episode 261: CAR T-Cell Therapy for Hematologic Malignancies Requires Education and Navigation Episode 176: Oncologic Emergencies: Cytokine Release Syndrome ONS Voice articles: An Oncology Nurse's Guide to Bispecific Antibodies Bispecific Antibodies Cross-Discipline Cancer Care ONS Voice oncology drug reference sheets: Amivantamab-Vmjw Blinatumomab Epcoritamab-Bysp Glofitamab-Gxbm Mosunetuzumab-Axgb Tebentafusp-Tebn Teclistamab-Cqyv ONS book: Guide to Cancer Immunotherapy (second edition) ONS course: ONS/ONCC® Chemotherapy Immunotherapy Certificate™ Clinical Journal of Oncology Nursing article: Optimizing Transitions of Care in Multiple Myeloma Immunotherapy: Nurse Roles Other ONS resources: Bispecific Antibodies Video Bispecifics Huddle Card Cytokine Release Syndrome Huddle Card Immune Effector Cell–Associated Neurotoxicity Syndrome Huddle Card DailyMed homepage Hematology/Oncology Pharmacy Association late-breaking news article: The Emerging Use of Bispecific Antibodies with Chemotherapy in Diffuse Large B-Cell Lymphoma To discuss the information in this episode with other oncology nurses, visit the ONS communities. To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org Highlights From This Episode “It was 2014 that most of us think of as the beginning of bispecifics in cancer, and that was with approval of blinatumomab. That was granted accelerated approval for the treatment of patients with Philadelphia chromosome–negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia. It is a bispecific that targets CD19-expressing tumor cells and CD3 on T cells. It's the original bispecific T-cell engager and is often called a ‘BiTE.'” TS 2:11 “The term ‘bispecific' means that this is an artificial protein that's developed to hit two different antigens simultaneously. They can be two different epitopes on the same antigen. They can be an antigen on a cancer cell and CD3 on a T cell that kind of recruits the T cell to the cancer. So, there are different types [of bispecific antibodies]. The subtype that we often talk about are bispecific T-cell engagers, which are those bispecifics that do target the T cell. And currently, the target on the T cell that's utilized is the CD3 molecule. That's not the only one that will be used in the future because there's a lot of work being done on other types of T-cell engagers.” TS 4:21 “The targets for lymphoma are CD20. Those are bispecific T-cell engagers that hit CD20 on the lymphoma cell, as well as CD3 on a T cell. ... In myeloma, we have two different targets that have been utilized. One is BCMA or B-cell maturation antigen. That sits on the surface of myeloma cells and on some healthy B cells. ... There's also a target used in myeloma that's called GPRC5D, which stands for G protein–coupled receptor, class C, group 5, member D. ... In small cell lung cancer, there's delta-like ligand 3 (DLL3); it's part of the NOTCH pathway. ... And then this year, we've had a couple agents come out that target HER2.” TS 6:52 “[Toxicities] are very dependent on what your target is. ... The bispecific T-cell engager that's used in myeloma that targets the GPRC5D is also expressed on tissues that produce hard keratin like hair follicles and actually, within the tongue. So the toxicities that we see with that agent are something you wouldn't expect to see if you were using a myeloma agent. You see nail and skin issues. You see taste problems. So it's very specific about the target, which says to me, that every time a new one of these agents comes out, I have to learn about the target that helps me learn about the toxicity. I find that fascinating and really appreciate that.” TS 16:19 “Cytokine release syndrome has been one of the areas that drug development has really focused on to see how they can help mitigate the severity [of it]. ... [One of] the strategies that has been incorporated and studied in clinical trials is the step-up dosing scheme. [It's] where you give initial small doses and over time, increase the dose to the dose you're going to continue with. Usually, monitoring in the hospital is required by the FDA approval for anywhere from 28–48 hours for the first couple of doses. And that's a real common strategy that you'll see. Premedication with H2 blockers, H1 blockers, sometimes steroids. These are also things that are incorporated within the approvals of these drugs and are important to look at.” TS 20:53
In our exclusive interview, Dr Shitara discussed preliminary efficacy data with CAR T-cell therapy in gastrointestinal cancers; highlighted challenges related to durability of response, patient selection, and manufacturing logistics with these therapies; and outlined ongoing biomarker analyses exploring tumor microenvironment factors influencing resistance.
For decades, Dr. Bruce Levine has been at the forefront of cancer research, pioneering CAR T-cell therapy—a treatment that harnesses a patient’s own immune system to fight cancer. On a recent conversation with Asia Tabb, Levine shared his journey and the promise of this innovative therapy.Support WITF: https://www.witf.org/support/give-now/See omnystudio.com/listener for privacy information.
Featuring an interview with Dr Beth Faiman, including the following topics: Clinical practice background and historical view of treatment for multiple myeloma (MM) (0:00) Fundamental principles associated with chimeric antigen receptor (CAR) T-cell therapy (7:19) Sequencing of CAR T-cell therapy and bispecific antibodies in the MM treatment landscape (9:00) Patient eligibility to receive CAR T-cell therapy (13:23) Differentiating among approved CAR T-cell therapies for MM (18:18) Durability of responses to CAR T-cell therapy for MM (24:01) Neurotoxicity with CAR T-cell therapies for MM (26:26) Minimal residual disease monitoring in MM (29:39) Support systems for the management of toxicities associated with CAR T-cell therapy (35:10) Patients with MM experiencing durable responses to CAR T-cell therapy (43:11) NCPD information and select publications
Dr Beth Faiman from Case Comprehensive Cancer Center in Cleveland, Ohio, discusses nursing considerations with CAR T-cell therapy for patients with multiple myeloma. NCPD information and select publications here.
In this episode, editor in chief Joseph E. Safdieh, MD, FAAN, highlights articles about a promising blood test to distinguish Parkinson's disease from dementia with Lewy bodies, how CAR T-cell therapies are showing potential for patients with glioblastoma, and a new wireless electroencephalogram device that can even monitor young children with epilepsy.
With Dr Larry Bacon, Consultant Haematologist from St James's Hospital, and Dr Nicola Gardiner, Chief Medical Scientist at the Cryobiology Laboratory Stem Cell Facility at St James's.Newsround with Dr Ruth Freeman from Research Ireland and science communicator Fergus McAuliffe.
Send us a textThe future of cancer treatment is on the horizon, but can we afford it, regulate it, and deliver it at scale?In this episode of the HealthBiz Podcast, Dr. Jason Bock, Co-founder and CEO of CTMC, discusses the progress of CAR T cell therapy, the challenges of scaling manufacturing for personalized treatments, and how new payment and policy models can support broader access. He shares inspiring patient success stories, insights into the future of solid tumor therapies, and CTMC's mission to bring advanced therapies to more patients, faster.
In the second installment of this two-part series, Dr. Jeff Ratliff and Dr. Brin E. Freund discuss clinical guidance for managing patients who may experience neurotoxicity from CAR T-cell, with a specific focus on seizure risk. Show reference: https://www.neurology.org/doi/10.1212/WNL.0000000000213535
In part one of this two-part series, Dr. Jeff Ratliff and Dr. Brin E. Freund discuss the incidence of acute symptomatic seizures during CAR T-cell therapy. Show reference: https://www.neurology.org/doi/10.1212/WNL.0000000000213535
Dr. Jeff Ratliff talks with Dr. Brin E. Freund about the evaluated incidence and risk factors for acute symptomatic seizures during CAR T-cell therapy. Read the related article in Neurology®. Disclosures can be found at Neurology.org.
© 2020-2026 Ivy Podcast Discovery LLC
